Bausch Health Companies Inc.
NYSE:BHCDrug Manufacturers - Specialty & Generic
-$0.11 today
- Market cap
- $3.27B
- Beta
- 0.41
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$3.19
Volume 6.83M
Average 1.70M
BHC Inventory
Cash effect of the change in inventory; building inventory consumes cash.
Bausch Health Companies Inc.NYSE: BHC
Inventory · Q2 FY2026 · quarter ended Jun 2026
Inventory turns negative
Q2 FY2026 inventory was -$22M, compared with $7M a year earlier. Trailing-twelve-month inventory was -$25.08M. Over 3 fiscal years it compounded at -60.5% a year.
Context
- Inventory amounted to 0.1% of revenue in FY2025, down 2.7 pp from a year earlier.
- Inventory grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly inventory holds near -$22M or moves back toward the trailing-twelve-month quarterly average of -$6.27M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Inventory history
USD · from the cash flow
- Latest · FY2025
- (12.21M) USD
- Year-over-year change
- +95.4%
| Period | Period end | Inventory | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (12.21M) | +95.4% |
| FY2024 | 2024-12-31 | (267M) | +17.1% |
| FY2023 | 2023-12-31 | (322M) | -62.6% |
| FY2022 | 2022-12-31 | (198M) | -1137.5% |
| FY2021 | 2021-12-31 | (16M) | — |
Inventory vs competitors
How BHC compares with its peers on the latest reported figures
- BHC's LTM Jun 2026 inventory of $25.08M is the 4th largest of the 11 companies compared; the peer median is $1.16M.
- Its year-over-year change of -78.0% is the 6th highest of 8, against a peer median of +64.6%.
- Inventory amounts to 0.2% of revenue for BHC, versus a peer median of 0.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $110.5M | +236.8% | -7.3% | 2.7% | |
| LTM Mar 2026 | $86.28M | +64.6% | +40.6% | 15.4% | |
| LTM Jun 2026 | $43.06M | +280.2% | +15.5% | 3.2% | |
| LTM Jun 2026 | $25.08M | -78.0% | -60.5% | 0.2% | |
| LTM Mar 2026 | $15.62M | -9023.4% | — | 2.6% | |
| LTM Mar 2026 | $14M | +250.0% | -50.6% | 0.4% | |
| LTM Mar 2026 | $5.77M | -70.0% | -36.8% | 0.6% | |
| LTM Jun 2025 | $2.31M | -146.7% | — | 0.4% | |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | $0 | — | — | 0.0% |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | — | |
| Peer median (excluding BHC) | $1.16M | +64.6% | -7.3% | 0.6% | |
Competitors are the stored peer set for BHC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (937M) | (212M) | (611M) | (72M) | 120M |
| Depreciation & Amortization | 1.55B | 1.39B | 1.26B | 1.27B | 1.21B |
| Deferred Income Tax | (225M) | (176M) | 51M | 66M | 80M |
| Stock-Based Compensation | 128M | 126M | 132M | 150M | 216M |
| Change in Working Capital | (128M) | (396M) | (582M) | 7M | (222.83M) |
| Accounts Receivables | (229M) | (57M) | (195M) | (216M) | (136.35M) |
| Inventory | (16M) | (198M) | (322M) | (267M) | (12.21M) |
| Accounts Payables | 121M | (75M) | 158M | 357M | (77.33M) |
| Other Working Capital | (4M) | (66M) | (223M) | 133M | 3.05M |
| Other Non-Cash Items | 1.04B | (1.46B) | 778M | 179M | (1.17M) |
| Operating Cash Flow | 1.43B | (728M) | 1.03B | 1.6B | 1.4B |
| Capital Expenditures | (283M) | (268M) | (272M) | (337M) | (397M) |
| Acquisitions (Net) | 0 | (45M) | (1.89B) | 0 | 0 |
| Purchases of Investments | (19M) | (17M) | (27M) | (12M) | (11M) |
| Sales of Investments | 15M | 22M | 26M | 14M | 8M |
| Other Investing Activities | 682M | (45M) | (39M) | (119M) | (195M) |
| Investing Cash Flow | 409M | (303M) | (2.15B) | (454M) | (595M) |
| Debt Repayment | (1.34B) | (1.01B) | 1.58B | (799M) | (648.15M) |
| Common Stock Issued | 0 | 675M | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | (26M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (173M) | (139M) | (106M) | (43M) | (93.85M) |
| Financing Cash Flow | (1.51B) | (474M) | 1.48B | (868M) | (742M) |
| Effect of Forex Changes | (19M) | (23M) | 9M | (36M) | 61M |
| Net Change in Cash | 303M | (1.53B) | 371M | 239M | 124M |
| Free Cash Flow | 1.14B | (996M) | 760M | 1.26B | 1B |
Bausch Health Companies Inc.
NYSE:BHC
Intrinsic Alpha fair value
Locked
Current Price
$8.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.